<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.02">
 <iati-activity hierarchy="1" iati-activities:version="2.02" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-903-SPI-10213</iati-identifier>
  <reporting-org ref="XM-DAC-903" type="40">
   <narrative xml:lang="EN">International Finance Corporation</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Pliva Project</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">The project supports the growth and strategic development of Pliva, the leading pharmaceutical company in Central and Eastern Europe, and the only one that  has produced a blockbuster drug through its original research.  Plivas strategy for the future is to continue to build on its existing R&amp;D expertise by focusing on both original research, and generic drug development.     IFC investment will support the construction and outfitting of a new 25,000 square meter Research and Development facility.  Currently, the company&apos;&apos;s R&amp;D is conducted in three different locations and suffers from space limitations.  Consolidation of R&amp;D activities in one state of the art facility will increase efficiency and multi-disciplinary interaction.  The layout and infrastructure of the new facility will ensure that all Pliva&apos;&apos;s R&amp;D activities will be performed in compliance with international quality requirements, or &quot;Good Laboratory Practice&quot; (GLP).  About 55% of the facility will be dedicated to new product development and 45% of the facility will be dedicated to original research.  The department for new product registration will also be located in the new facility.  The investment will also result in  a significant improvement in the working conditions of the scientists by increasing laboratory space per scientist to international standards. Pliva&apos;&apos;s new R&amp;D facility will employ about 500 people.     The project is expected to have a broader positive impact on Croatian society through providing local scientists employment opportunities in their own country, helping to curb the high level of &quot;brain drain&quot; to employment opportunities outside of Croatia.  Despite Pliva&apos;&apos;s impressive financial performance, to date, the perceived country and macroeconomic risks have made it difficult for the Company to secure adequate long term financing at a reasonable cost.  The World Bank Group&apos;&apos;s priorities in Croatia have been to encourage private sector development and to support this process through rehabilitating the country&apos;&apos;s industrial asset base and environmental standards. Finally, this project is compatible with IFC&apos;&apos;s mission of attracting foreign investment and assisting through financing and advisory work with the restructuring and privatisation of formerly socially-owned enterprises.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN"></narrative>
  </description>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Pliva d.d.</narrative>
  </participating-org>
  <participating-org activity-id="XM-DAC-903-SPI-10213" ref="XM-DAC-903" role="1" type="40"></participating-org>
  <activity-status code="3"></activity-status>
  <activity-date iso-date="2000-11-17" type="1"></activity-date>
  <activity-date iso-date="2000-12-06" type="2"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">International Finance Corporation</narrative>
   </organisation>
   <telephone>+12024733800</telephone>
   <email>ccspg@ifc.org</email>
   <website>www.ifc.org</website>
   <mailing-address>
    <narrative xml:lang="EN">2121 Pennsylvania Avenue, NW Washington DC 20433</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">mkarner@ifc.org</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN"></narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="HR" percentage="100">
   <narrative xml:lang="EN">Croatia</narrative>
  </recipient-country>
  <location ref="HR-Croatia">
   <location-reach code="1"></location-reach>
   <location-id code="1453782" vocabulary="G1"></location-id>
   <name>
    <narrative xml:lang="EN">The project includes the construction and outfitting of a new 25,000 square meter Research Institute adjacent to   Pliva&apos;&apos;s   existing facilities in Zagreb, Croatia.  Project completion is targeted for the end of 2002.</narrative>
   </name>
   <description>
    <narrative xml:lang="EN">Location description</narrative>
   </description>
   <activity-description>
    <narrative xml:lang="EN">A description that qualifies the activity taking place at the location.</narrative>
   </activity-description>
   <administrative code="1453782" level="1" vocabulary="G1"></administrative>
   <point srsName="http://www.opengis.net/def/crs/EPSG/0/4326">
    <pos>45.1666720000 15.5000000000</pos>
   </point>
   <exactness code="2"></exactness>
   <location-class code="1"></location-class>
   <feature-designation code="ADMF"></feature-designation>
  </location>
  <sector percentage="100" vocabulary="11" vocabulary-uri="http://www.census.gov/cgi-bin/sssd/naics/naicsrch?chart=2012">
   <narrative xml:lang="EN">FA - Pharmaceuticals and Medicine</narrative>
  </sector>
  <country-budget-items vocabulary="1">
   <budget-item code="7.2.1" percentage="100" vocabulary="1">
    <description>
     <narrative xml:lang="EN">Total: $35.00 million</narrative>
    </description>
   </budget-item>
  </country-budget-items>
  <collaboration-type code="6"></collaboration-type>
  <default-flow-type code="35"></default-flow-type>
  <default-finance-type code="411"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget type="1">
   <period-start iso-date="2000-11-17"></period-start>
   <period-end iso-date="2001-06-30"></period-end>
   <value currency="USD" value-date="2000-11-17">0</value>
  </budget>
  <budget type="1">
   <period-start iso-date="2000-11-17"></period-start>
   <period-end iso-date="2001-06-30"></period-end>
   <value currency="USD" value-date="2000-11-17">35000000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2000-11-17"></transaction-date>
   <value currency="USD" value-date="2000-11-17">35000000</value>
   <receiver-org>
    <narrative xml:lang="EN">Pliva d.d.</narrative>
   </receiver-org>
   <flow-type code="35"></flow-type>
   <finance-type code="411"></finance-type>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2000-11-17"></transaction-date>
   <value currency="USD" value-date="2000-11-17">0</value>
   <receiver-org>
    <narrative xml:lang="EN">Pliva d.d.</narrative>
   </receiver-org>
   <flow-type code="35"></flow-type>
   <finance-type code="510"></finance-type>
  </transaction>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/project-detail/SPI/10213/pliva-project">
   <title>
    <narrative xml:lang="EN">Summary of Project Information</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
 </iati-activity>
</iati-activities>
